DHR
Danaher Corporation
DHR has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over DHR overall, supported by stronger fundamentals.
DHR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Stable |
DHR's profitability and cash flow are currently strong, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 26x | $232 | — |
| Cheap | 29x | $180 | -22% |
| Current | 38x | $232 | — |
| Fair | 39x | $239 | +2.8% |
| Expensive | 45x | $276 | +19% |
Historical ranges are pointers, not guarantees.
DHR's PE is in its fair range at 38x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over DHR in the historical PE scenario, which offers more potential upside but is not a forecast.
DHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for DHR, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
DHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.09 | +49% |
| Q3 2026 | $6.12 | +26% |
| Q2 2026 | $5.64 | +20% |
| Q1 2026 | $5.18 | +0.4% |
| Q4 2025 | $5.05 | -4.5% |
| Q3 2025 | $4.86 | -7.3% |
| Q2 2025 | $4.71 | -16% |
| Q1 2025 | $5.16 | -13% |
| Q4 2024 | $5.29 | -17% |
DHR's earnings per share have fallen from their peak: $6.12 over the past year, against $9.66 in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over DHR on earnings, with more consistent year-over-year improvement.
DHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.6B | +8.3% |
| Q2 2026 | $6.3B | +5.5% |
| Q1 2026 | $6B | +3.7% |
| Q4 2025 | $6.8B | +4.6% |
| Q3 2025 | $6.1B | +4.4% |
| Q2 2025 | $5.9B | +3.4% |
| Q1 2025 | $5.7B | -0.9% |
| Q4 2024 | $6.5B | +2.1% |
DHR's revenue is recovering but still below its 2022 peak: $6.6B last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | -0.1 points |
| Q2 2026 | 18% | +5.2 points |
| Q1 2026 | 23% | +0.4 points |
| Q4 2025 | 22% | +0.2 points |
| Q3 2025 | 19% | +2.5 points |
| Q2 2025 | 13% | -7.5 points |
| Q1 2025 | 22% | -0.4 points |
| Q4 2024 | 22% | +0.9 points |
DHR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
DHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +19% |
| Q2 2026 | $1.3B | +16% |
| Q1 2026 | $1.1B | +2.9% |
| Q4 2025 | $1.7B | +16% |
| Q3 2025 | $1.4B | +13% |
| Q2 2025 | $1.1B | -3.5% |
| Q1 2025 | $1.1B | -27% |
| Q4 2024 | $1.5B | +24% |
DHR's free cash flow has been positive every quarter for seven years: $5.7B over the past year, up 14% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
DHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -800K shares |
| 1 year | -1% | -6.9M shares |
| 3 years | -5.2% | -39.1M shares |
| 5 years | -2.8% | -20.2M shares |
| Available history | -2.6% | -18.7M shares |
DHR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $894M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $2B |
| Q2 2025 | — |
| Q1 2025 | $1.1B |
| Q4 2024 | $809M |
DHR spent $894M buying back its own shares over the past year, down 77% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 2.9x | Moderate |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 1.9x | Healthy |
DHR's net debt is about 2.6 years of its operating earnings (EBITDA), up from 2.2 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over DHR on leverage, with a lower net debt burden relative to earnings.
DHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.3 | Neutral |
| Stochastic | 84.4 | Overbought |
DHR's weekly RSI is 62 (neutral) and its Stochastic is 84 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DHR PE vs Healthcare Sector
| Metric | DHR | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 26x | 47% above |
| PE % | 42 | 29 | 13 pts above |
DHR is trading at 38x earnings, a 47% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over DHR on valuation relative to its sector.
DHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $226.6 | 2.5% above |
| 20 week MA | $213.1 | 9% above |
| 50 week MA | $205.7 | 13% above |
| 100 week MA | $206.5 | 12% above |
| 200 week MA | $221.0 | 5.1% above |
DHR has climbed back above all five of its weekly moving averages, and it's now 5.1% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
DHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.5 | $196.3 | +45% |
| 2021 | $196.3 | $284.4 | +45% |
| 2022 | $284.4 | $230.3 | -19% |
| 2023 | $230.3 | $231.3 | +0.4% |
| 2024 | $231.3 | $231.1 | -0.1% |
| 2025 | $231.1 | $230.3 | -0.3% |
| 2026 YTD | $230.3 | $232.2 | +0.8% |
DHR has finished lower in three of the last six years. It's up 0.8% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DHR on returns for 2026, with the stronger performance.